Mark C. Markowski

2.7k total citations
90 papers, 1.4k citations indexed

About

Mark C. Markowski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark C. Markowski has authored 90 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 32 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark C. Markowski's work include Prostate Cancer Treatment and Research (67 papers), Radiopharmaceutical Chemistry and Applications (30 papers) and Prostate Cancer Diagnosis and Treatment (17 papers). Mark C. Markowski is often cited by papers focused on Prostate Cancer Treatment and Research (67 papers), Radiopharmaceutical Chemistry and Applications (30 papers) and Prostate Cancer Diagnosis and Treatment (17 papers). Mark C. Markowski collaborates with scholars based in United States, Canada and Germany. Mark C. Markowski's co-authors include Emmanuel S. Antonarakis, Mario A. Eisenberger, Samuel R. Denmeade, Edward P. Gelmann, Michael A. Carducci, Cai Bowen, Jun Luo, Karen S. Sfanos, Kotohiko Kimura and Pedro Isaacsson Velho and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Mark C. Markowski

82 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark C. Markowski United States 22 946 525 400 277 250 90 1.4k
Ronald Tutrone United States 21 1.1k 1.2× 426 0.8× 226 0.6× 398 1.4× 179 0.7× 111 1.7k
Edgar Ben‐Josef United States 19 973 1.0× 324 0.6× 408 1.0× 176 0.6× 339 1.4× 34 1.6k
Thibault De La Motte Rouge France 21 495 0.5× 692 1.3× 479 1.2× 329 1.2× 164 0.7× 99 1.7k
Markku H. Vaarala Finland 22 552 0.6× 572 1.1× 286 0.7× 220 0.8× 90 0.4× 53 1.5k
Alton B. Kremer United States 11 850 0.9× 660 1.3× 551 1.4× 405 1.5× 146 0.6× 13 1.4k
Lyly Le Canada 13 544 0.6× 622 1.2× 465 1.2× 281 1.0× 108 0.4× 22 1.3k
Giulia Pasello Italy 23 1.1k 1.2× 510 1.0× 1.1k 2.7× 349 1.3× 142 0.6× 165 2.0k
Kazuki Yamanaka Japan 23 512 0.5× 756 1.4× 487 1.2× 335 1.2× 85 0.3× 65 1.6k
Henrik Roed Denmark 22 525 0.6× 309 0.6× 755 1.9× 119 0.4× 342 1.4× 56 1.8k
Dongmei Yuan China 19 378 0.4× 706 1.3× 478 1.2× 420 1.5× 127 0.5× 64 1.5k

Countries citing papers authored by Mark C. Markowski

Since Specialization
Citations

This map shows the geographic impact of Mark C. Markowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Markowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Markowski more than expected).

Fields of papers citing papers by Mark C. Markowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Markowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Markowski. The network helps show where Mark C. Markowski may publish in the future.

Co-authorship network of co-authors of Mark C. Markowski

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Markowski. A scholar is included among the top collaborators of Mark C. Markowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Markowski. Mark C. Markowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Singh, Rajiv K., Zirui Jiang, Vanessa F. Merino, et al.. (2024). Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma. Frontiers in Oncology. 14. 1432286–1432286.
2.
Marshall, Catherine H., Lukasz P. Gondek, Changxue Lu, et al.. (2024). Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate. 84(10). 954–958. 10 indexed citations
3.
Carducci, Michael A., et al.. (2024). Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer. The Prostate. 85(4). 391–394. 2 indexed citations
4.
Gebrael, Georges, Hao Wang, Michael A. Carducci, et al.. (2023). 2023 Kidney Cancer Research Summit Abstracts. The Oncologist. 28(Supplement_1). S1–S1. 1 indexed citations
5.
Wang, Hao, et al.. (2023). ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations. The Oncologist. 28(Supplement_1). S1–S1. 7 indexed citations
6.
Denmeade, Samuel R., Laura A. Sena, Hao Wang, Emmanuel S. Antonarakis, & Mark C. Markowski. (2023). Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. The Oncologist. 28(6). 465–473. 4 indexed citations
7.
Chatta, Gurkamal, Christos E. Kyriakopoulos, Nicholas Iannotti, et al.. (2023). 1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results. Annals of Oncology. 34. S982–S983. 4 indexed citations
8.
Werner, Rudolf A., Susanne Lütje, Markus Essler, et al.. (2023). Lack of repeatability of radiomic features derived from PET scans: Results from a 18F‐DCFPyL test–retest cohort. The Prostate. 83(6). 547–554. 9 indexed citations
9.
Markowski, Mark C., Ronald Tutrone, Christopher Pieczonka, et al.. (2022). A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent. Clinical Cancer Research. 28(13). 2789–2795. 28 indexed citations
10.
Denmeade, Samuel R., Emmanuel S. Antonarakis, & Mark C. Markowski. (2022). Bipolar androgen therapy (BAT): A patient's guide. The Prostate. 82(7). 753–762. 19 indexed citations
11.
Ged, Yasser, Mark C. Markowski, Nirmish Singla, & Steven P. Rowe. (2022). The shifting treatment paradigm of metastatic renal cell carcinoma. Nature Reviews Urology. 19(11). 631–632. 7 indexed citations
12.
Markowski, Mark C., Sushant K. Kachhap, Angelo M. De Marzo, et al.. (2021). Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer. 20(2). 97–101. 17 indexed citations
13.
Markowski, Mark C., Eugene Shenderov, Mario A. Eisenberger, et al.. (2020). Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. The Prostate. 80(5). 407–411. 25 indexed citations
14.
15.
Deek, Matthew P., Ryan Phillips, Daniel Y. Song, et al.. (2019). Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology*Biology*Physics. 105(5). 948–956. 32 indexed citations
16.
Velho, Pedro Isaacsson, Wei Fu, Hao Wang, et al.. (2019). Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European Urology. 77(1). 14–21. 66 indexed citations
17.
Meyer, Alexa, Michael A. Carducci, Samuel R. Denmeade, et al.. (2019). Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Annals of Nuclear Medicine. 33(8). 617–623. 50 indexed citations
18.
Sfanos, Karen S., Mark C. Markowski, Lauren B. Peiffer, et al.. (2018). Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer and Prostatic Diseases. 21(4). 539–548. 104 indexed citations
19.
Markowski, Mark C., Cai Bowen, & Edward P. Gelmann. (2008). Inflammatory Cytokines Induce Phosphorylation and Ubiquitination of Prostate Suppressor Protein NKX3.1. Cancer Research. 68(17). 6896–6901. 49 indexed citations
20.
Kimura, Kotohiko, Mark C. Markowski, Lisa C. Edsall, Sarah Spiegel, & Edward P. Gelmann. (2003). Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death and Differentiation. 10(2). 240–248. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald Tutrone Breakdown of academic impact, for papers by Edgar Ben‐Josef Breakdown of academic impact, for papers by Thibault De La Motte Rouge Breakdown of academic impact, for papers by Markku H. Vaarala Breakdown of academic impact, for papers by Alton B. Kremer Breakdown of academic impact, for papers by Lyly Le Breakdown of academic impact, for papers by Giulia Pasello Breakdown of academic impact, for papers by Kazuki Yamanaka Breakdown of academic impact, for papers by Henrik Roed Breakdown of academic impact, for papers by Dongmei Yuan
Rankless by CCL
2026